| Literature DB >> 32285009 |
Jasper Nijkamp1, Theo J M Ruers1,2, Esther N D Kok1, Roeland Eppenga1, Koert F D Kuhlmann1, Harald C Groen1, Ruben van Veen1, Jolanda M van Dieren3, Thomas R de Wijkerslooth3, Monique van Leerdam3, Doenja M J Lambregts4, Wouter J Heerink1, Nikie J Hoetjes1, Oleksandra Ivashchenko1, Geerard L Beets1, Arend G J Aalbers1.
Abstract
In the past decades, image-guided surgery has evolved rapidly. In procedures with a relatively fixed target area, like neurosurgery and orthopedics, this has led to improved patient outcomes. In cancer surgery, intraoperative guidance could be of great benefit to secure radical resection margins since residual disease is associated with local recurrence and poor survival. However, most tumor lesions are mobile with a constantly changing position. Here, we present an innovative technique for real-time tumor tracking in cancer surgery. In this study, we evaluated the feasibility of real-time tumor tracking during rectal cancer surgery. The application of real-time tumor tracking using an intraoperative navigation system is feasible and safe with a high median target registration accuracy of 3 mm. This technique allows oncological surgeons to obtain real-time accurate information on tumor location, as well as critical anatomical information. This study demonstrates that real-time tumor tracking is feasible and could potentially decrease positive resection margins and improve patient outcome.Entities:
Keywords: Rectal cancer; Surgical oncology
Year: 2020 PMID: 32285009 PMCID: PMC7142120 DOI: 10.1038/s41698-020-0115-0
Source DB: PubMed Journal: NPJ Precis Oncol ISSN: 2397-768X
Patient characteristics.
| Characteristics | Feasibility phase, | Test phase, |
|---|---|---|
| Sex | ||
| Male | 10 (66.7) | 11 (68.7) |
| Female | 5 (33.3) | 5 (31.3) |
| Median age (year) (min–max) | 62.0 (39–78) | 58.0 (37–85) |
| Clinical tumor and nodal stagea | ||
| cT2N0 | 0 (0.0) | 1 (6.3) |
| cT2N+ | 2 (13.3) | 2 (12.5) |
| cT3N0 | 6 (40.0) | 8 (50.0) |
| cT3N+ | 5 (33.3) | 5 (31.3) |
| cT4N0 | 1 (6.7) | 0 (0.0) |
| cT4N+ | 1 (6.7) | 0 (0.0) |
| Median distance between anorectal verge and tumor (cm) | 3.0 (0–9) | 3.0 (0–6) |
| Neoadjuvant treatment | ||
| Radiotherapy (5 × 5 Gy) | 3 (20.0) | 1 (6.3) |
| Radiotherapy (5 × 5 Gy) + chemotherapy | 5 (33.3) | 4 (25.0) |
| Chemoradiation (25 × 2 Gy + capecitabine) | 7 (46.7) | 9 (56.3) |
| Chemoradiation + chemotherapy | 0 (0) | 1 (6.3) |
| Chemoradiation and contact radiotherapy | 0 (0) | 1 (6.3) |
aClinical tumor and nodal stage at diagnosis.
Fig. 1Surgical navigation user interface during surgery showing the planning CT with segmentations (top-left corner: coronal view; top-right corner: sagittal view; lower-left corner: axial view) and 3D model (lower-right corner).
Visible segmentations: bones (white), arteries (red), veins (blue), ureters/kidneys (yellow), and tumor (green). The visible slice of the CT scans is based on the location of the tip of the surgical pointer which is highlighted with yellow arrows.
Fig. 2Schematic overview of in vivo tumor sensor with the tip positioned by the surgeon at the rectal tumor.
The sensor is fixated with sutures in the perineal area (Alamy Stock Photo (https://www.alamy.com/search.html?qt=Sagittal%20View%20of%20a%20Female%20Pelvis&imgt=0), used and edited with permission).
Fig. 3An example to illustrate the real-time tumor tracking by the navigation system.
The top two images show the position of the rectal tumor in rest. In the lower four images, the rectum is moved to the right and left. Note that the green segmentation area follows the real-time tumor position in the navigation images on the right, while the CT scan on the left (still) shows the original position of the tumor. Visible segmentation: bones (white), arteries (red), veins (blue), ureters/kidneys (yellow), and tumor (green).
Treatment characteristics.
| Characteristics | Feasibility phase, | Test phase, |
|---|---|---|
| Fiducial markers | 8 (53.3) | 16 (100.0) |
| Type of surgery | ||
| Open APR | 4 (26.7) | 4 (25.0) |
| Lap. APR | 3 (20.0) | 4 (25.0) |
| Open LAR | 5 (33.3) | 3 (18.8) |
| Lap. LAR | 3 (20.0) | 3 (18.8) |
| No navigated surgery performed | 0 (0) | 2 (12.5) |
| Surgery with navigation | 11 (73.3) | 14 (87.5) |
| Technical navigation errors | ||
| Tumor sensor-related | 4 (26.7) | 0 (0) |
| Registration-related | 0 (0) | 1 (6.3) |
| Study-related severe adverse eventsa | 0 (0) | 1 (6.3) |
| Intraoperative complicationsb | ||
| Navigation related | 0 (0) | 0 (0) |
| Non-navigation related | 0 (0) | 1 (6.3) |
| Median extra time needed (min–max) | 31 (21–46) | 21 (15–30) |
aOne patient suffered from an intra-abdominal infection possibly related to the fiducial placement.
bOne patient experienced iatrogenic injury of the ureter, not caused or related to the navigation system, and required reimplantation of the ureter in the bladder.